Crispr Therapeutics (CRSP) Rating Reiterated by Oppenheimer – The Lincolnian Online
The Lincolnian Online |
Crispr Therapeutics (CRSP) Rating Reiterated by Oppenheimer
The Lincolnian Online Crispr Therapeutics (NASDAQ:CRSP)'s stock had its “hold” rating reiterated by Oppenheimer in a report issued on Thursday. A number of other brokerages also recently weighed in on CRSP. BidaskClub downgraded Crispr Therapeutics from a “buy” rating to a … Cann Reaffirms “Hold” Rating for Crispr Therapeutics (NASDAQ … Crispr Therapeutics AG (CRSP) Insider Tyler Dylan-Hyde Sells … |
